Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neurocrine Biosciences

122.96
+0.14000.11%
Post-market: 122.960.00000.00%16:26 EDT
Volume:1.19M
Turnover:146.79M
Market Cap:12.17B
PE:41.58
High:123.99
Open:122.61
Low:121.87
Close:122.82
Loading ...
Feb 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 02, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 01, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities